Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].

Wu S, Chen MY, Luo JC, Wei L, Chen Z.

Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):873-6. doi: 10.3760/cma.j.issn.0253-3766.2012.11.017. Chinese.

PMID:
23291141
2.

[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis].

YANG H, FU JH, LIU MZ, FANG WT, WANG JM, CHEN YP, CHEN ZJ, XIANG JQ, YANG HJ, MAO WM, ZHENG X, ZHU CC, KONG M, HAN YT, LI T.

Zhonghua Yi Xue Za Zhi. 2012 Apr 17;92(15):1028-32. Chinese.

PMID:
22781642
3.
4.
5.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.

J Clin Oncol. 2005 Dec 1;23(34):8636-45. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.

PMID:
16275937
6.

Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).

Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group..

Jpn J Clin Oncol. 2013 Jul;43(7):752-5. doi: 10.1093/jjco/hyt061.

8.

Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.

Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F, Fila G.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7.

PMID:
15145166
9.

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.

Am J Clin Oncol. 2010 Dec;33(6):624-8. doi: 10.1097/COC.0b013e3181bead92.

PMID:
20142726
10.

A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.

Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J.

Chin J Cancer. 2010 Mar;29(3):321-4.

11.

Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).

Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W; Kitasato Digestive Disease and Oncology Group..

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):872-9. doi: 10.1016/j.ijrobp.2014.03.030.

PMID:
24867539
13.

Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.

Eisterer W, DE Vries A, Kendler D, Spechtenhauser B, Königsrainer A, Nehoda H, Virgolini I, Lukas P, Bechter O, Wöll E, Ofner D.

Anticancer Res. 2011 Dec;31(12):4407-12.

PMID:
22199307
14.

Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.

Emi M, Hihara J, Hamai Y, Aoki Y, Okada M, Kenjo M, Murakami Y.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1499-505. doi: 10.1007/s00280-012-1853-7.

PMID:
22382882
15.

Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG)..

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033.

PMID:
20932658
16.

Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.

Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):111-22.

PMID:
15337546
17.

A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K.

Radiother Oncol. 2008 Jun;87(3):398-404. doi: 10.1016/j.radonc.2008.03.006.

PMID:
18405987
19.

Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.

Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, Bonetti A, Campostrini F, Gardani G, Ardizzoia A, Dondi D, Guaraldi M, Cavallo R, Tomio L, Gava A; Gruppo di Studio Tumori della Testa e del Collo XRP 6976 F/2501 Study..

Ann Oncol. 2010 Jul;21(7):1515-22. doi: 10.1093/annonc/mdp573.

PMID:
20032123
20.

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.

Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K.

Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048.

Items per page

Supplemental Content

Support Center